 | This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
A Molecular Tumor Board (MTB) is a dedicated group of medical experts to evaluate hard-to-treat cancers and provide a personalized healthcare opportunity. [1] It has also been called a Sequencing Tumor Board [2] and it is characterized by the in-depth application of molecular analysis (e.g. genomics and transcriptomics) for a single patient. [2] Molecular Tumor Boards are considered most useful for cancer types for which therapies are not effective, for example, in the case of heterogeneous sarcomas. [1] The boards are composed by clinical oncologists and pathologists alongside other specialists, which vary from institution to institution, but might include geneticists, bioinformaticians and molecular biologists. [1] MTBs are considered to improve clinical outcomes for patients with tumors with unique molecular profiles. [3]
Molecular Tumour Boards have been used by a number of institutions, like the Dartmouth–Hitchcock Medical Center, the Johns Hopkins Hospital [4] and the Moffitt Cancer Center. [5]
References
- ^ a b c Luchini C, Lawlor RT, Milella M, Scarpa A (September 2020). "Molecular Tumor Boards in Clinical Practice". Trends in Cancer. 6 (9): 738–744. doi: 10.1016/j.trecan.2020.05.008. PMID 32517959. S2CID 219561620.
- ^ a b Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. (November 2011). "Personalized oncology through integrative high-throughput sequencing: a pilot study". Science Translational Medicine. 3 (111): 111ra121. doi: 10.1126/scitranslmed.3003161. PMC 3476478. PMID 22133722.
- ^ Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, et al. (October 2020). "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications. 11 (1): 4965. Bibcode: 2020NatCo..11.4965K. doi: 10.1038/s41467-020-18613-3. PMC 7532150. PMID 33009371.
- ^ Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, et al. (November 2017). "Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board". JCO Precision Oncology. 2017 (1): 1–19. doi: 10.1200/po.16.00046. PMC 6039131. PMID 30003184.
- ^ Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, et al. (February 2017). "Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience". The Oncologist. 22 (2): 144–151. doi: 10.1634/theoncologist.2016-0195. PMC 5330702. PMID 28179575.
 | This oncology article is a stub. You can help Wikipedia by expanding it. |
| This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
A Molecular Tumor Board (MTB) is a dedicated group of medical experts to evaluate hard-to-treat cancers and provide a personalized healthcare opportunity. [1] It has also been called a Sequencing Tumor Board [2] and it is characterized by the in-depth application of molecular analysis (e.g. genomics and transcriptomics) for a single patient. [2] Molecular Tumor Boards are considered most useful for cancer types for which therapies are not effective, for example, in the case of heterogeneous sarcomas. [1] The boards are composed by clinical oncologists and pathologists alongside other specialists, which vary from institution to institution, but might include geneticists, bioinformaticians and molecular biologists. [1] MTBs are considered to improve clinical outcomes for patients with tumors with unique molecular profiles. [3]
Molecular Tumour Boards have been used by a number of institutions, like the Dartmouth–Hitchcock Medical Center, the Johns Hopkins Hospital [4] and the Moffitt Cancer Center. [5]
References
- ^ a b c Luchini C, Lawlor RT, Milella M, Scarpa A (September 2020). "Molecular Tumor Boards in Clinical Practice". Trends in Cancer. 6 (9): 738–744. doi: 10.1016/j.trecan.2020.05.008. PMID 32517959. S2CID 219561620.
- ^ a b Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. (November 2011). "Personalized oncology through integrative high-throughput sequencing: a pilot study". Science Translational Medicine. 3 (111): 111ra121. doi: 10.1126/scitranslmed.3003161. PMC 3476478. PMID 22133722.
- ^ Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, et al. (October 2020). "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications. 11 (1): 4965. Bibcode: 2020NatCo..11.4965K. doi: 10.1038/s41467-020-18613-3. PMC 7532150. PMID 33009371.
- ^ Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, et al. (November 2017). "Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board". JCO Precision Oncology. 2017 (1): 1–19. doi: 10.1200/po.16.00046. PMC 6039131. PMID 30003184.
- ^ Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, et al. (February 2017). "Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience". The Oncologist. 22 (2): 144–151. doi: 10.1634/theoncologist.2016-0195. PMC 5330702. PMID 28179575.
|
| This oncology article is a stub. You can help Wikipedia by expanding it. |